Benefit versus toxicity risk of digoxin in patients with COVID-19

Eur J Hosp Pharm. 2022 Nov;29(6):e9. doi: 10.1136/ejhpharm-2021-002880. Epub 2021 Jun 2.

Authors

Burcu Kelleci Cakir¹, Aygin Bayraktar-Ekincioglu², Kutay Demirkan²

Affiliations

¹ Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey burcukelleci@hacettepe.edu.tr.
² Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey.

No abstract available

Keywords: COVID-19; cardiology; drug-related side effects and adverse reactions; pharmacy administration; safety.

Publication types

Letter

MeSH terms

COVID-19 Drug Treatment*
Digoxin / adverse effects
Drug-Related Side Effects and Adverse Reactions*
Humans

Substances

Digoxin